The second patient was a 45-year-old Asian man. He was initially seen by dermatology with alopecia and a scaly rash on his face, elbow and hands. He was then diagnosed with early inflammatory arthritis and commenced steroids and methotrexate. He developed skin ulceration and respiratory symptoms with a CT chest showing features of COP. He was ANA negative but anti-Ro and anti-Scl-70 positive. He was given antibiotics, methylprednisolone and switched to mycophenolate mofetil. Whilst abroad he was admitted to hospital, diagnosed with anti-MDA5 positive amyopathic dermatomyositis and given methylprednisolone and cyclophosphamide. Cyclophosphamide was continued on his return to the UK, with PCP prophylaxis but he also required home oxygen. He was admitted to hospital with increasing breathlessness and given further methylprednisolone and treatment dose co-trimoxazole. Two weeks later he deteriorated further and repeat CT scan showed a pneumomediastinum. He received antibiotics, antifungals and rituximab but died after three days onITU. Discussion: Although in both cases it was recognised the patients had some form of inflammatory condition the diagnosis of anti-MDA5 positive dermatomyositis took some time. The lack of muscle involvement is typical and means clinicians need to give more thought to the possible diagnosis particularly when patients present with skin lesions and look specifically for MDA5 antibodies. These cases also show how rapidly the lung disease can progress. Being aware that a patient is MDA5 positive gives important information to the clinical team regarding the potential prognosis and in these cases it has been questioned whether these concerns were entirely relayed to the patients and their families. High serum ferritin, ground-glass opacities in all six lung fields and worsening of pulmonary infiltrates during therapy have been suggested as further poor prognosticfactors. Both patients presented particular challenges in trying to decide whether their deterioration was due to infection in the context of immunosuppression, disease progression or both and consequently full infection screens were performed including bronchoscopies at various points. Given how unwell both patients were all available treatments were considered. Once it was recognised how rapidly the lung disease was progressing they both received cyclophosphamide and rituximab. IV immunoglobulin was requested for both patients but only agreed for the first patient as he had proven PCP pneumonia. Key learning points: Anti-MDA5 positive dermatomyositis commonly presents with typical mucocutaneous lesions (such as cutaneous ulceration, alopecia and oral ulcers) which can differ from those seen in classical dermatomyositis. It is important to consider the possibility of anti-MDA5 positive dermatomyositisinapatientwithskinabnormalities andanormal CK, and in such circumstances request an extended myositis screen ensuring MDA5 is included. Patients who are MDA5 positive and have lung involvement often have rapidly progressive interstitial lung disease. Prognosis is especially poor when patients are admitted to ITU and worse than patients with anti-synthetase syndrome. Spontaneous pneumomediastinum can be a feature when the outcome is almost always poor in a ventilated patient. Treatment options are limited, generally aggressive immunosuppression is recommended when there is lung involvement and induction therapy with cyclophosphamide or rituximab has been tried. There are emerging reports of JAK inhibitors being used in dermatomyositis andso thismaybesomething toconsider inthis subsetof difficult to treat patients. Consideration should be given to vaccinating against influenza and pneumococcal infections as soon as possible, together with PCP prophylaxis and aggressive treatment of superadded infections. When appropriate patients and relatives should be made aware of the potentially poor prognosis. It is important to work closely with other specialities such as dermatology, respiratory and when necessary ITU. Due to the complexity and severityof this conditionan MDT approach is recommended.
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Rheumatology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom Introduction: Statins are a commonly used group of drugs which lowers low density lipoprotein (LDL) levels by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. Though they are effective and safe, about 0.1% patients on statins can develop severe myonecrosis orimmune mediated necrotising myopathy (IMNM). Here we present a case of IMNM secondary to atorvastatin exposure, resulting in severe muscle weakness and prolonged hospitalisation, and positive treatment response to intravenous immunoglobulin (IVIG).
Case description: A 59-year-old Caucasian lady with a history of hypothyroidism and hyperlipidaemia, presented with 5 weeks' history of progressive weakness in both upper and lower limbs which was preceded by flu like symptoms. She was also having swallowing difficulty and had neck-flexor weakness. There was MRC grade 2 power around hips, knees and shoulders, with normal power distally. She had been started on atorvastatin 10 mg6 months ago, which was stopped due to myalgia. She was admitted tothe hospital, andsoon developedrespiratorymuscle weakness. She had serial SVC assessment and required nasogastric feeding. Electromyography suggested myositis. MRI of the thighs showed extensive myositis, muscle biopsy confirmed necrotising myopathy. Autoantibodies were negative, but she had high titre HMGcoA reductase antibodies (anti-HMGCR). Creatine kinase levels on presentation was 24230 U/L, which increased to 31000 U/L. Initial SVC was 33% of predicted. CT scan of chest abdomen and pelvis did not reveal any malignancy. Cardiac MRI did not reveal myocarditis, though her troponin-T levels were raised1096 ng/L. She was non responsive to 3 pulses of 1 gm methyl-prednisolone. She was treated with IVIG, cyclophosphamide infusions and oral prednisolone. She made steady progress and was discharged with SVC of 70%, CK of 664 U/I, proximal muscle strength of 3/5 and feeding orally. She received 9cycles of 900 mgcyclophosphamide followed bymycophenolate mofetil 2gm/day. However, her CK levels plateaued to between 650 and 700; proximal lower limb power was fluctuating between 4 and 3. She received another course of IVIG-6 months after the onset of myositis which significantly improved her power, which sustained for around 4 months. The plan is to manage her with serialIVIG infusions. Discussion: Statins can cause adverse muscle related events, ranging from mild myalgia to severe myopathy and rhabdomyolysis. Rarely, patients can develop immune mediated necrotising myositis, as in our patient. IMNM can cause persisting myositis with predominantly proximal muscle weakness, and runs a protracted course. Statin-induced IMNM is associated with presence of anti HMGCR antibodies. There are no clinical trials to guide therapeutic decisions in IMNM, however some case series and observational studies have shown improvement with immunosuppression. IVIG have been shown to be effective in anti HMGCR associated IMNM, as inourcase. Even after stopping statins, IMNM can progress and patients can have prolonged weakness requiring immunosuppression. Around 50% patients continue to have significant weakness even after 2 years of treatment, indicating anunfavourable prognosis. Our patient continues to have waxing waning weakness with persistently raised CK, and IVIG infusions seems to give a rapid clinical response , though sustaining for 3 to 4 months, indicating a need for repeated infusions. The other treatment option remains rituximab, which has shown to have someefficacy inanti-SRP positive IMNM. Our patient had hypothyroidism, which is known to potentiate statin induced myopathy,however,strongassociationwithIMNMisnotestablished. Around 80% patients with anti HMGCR associated myositis have prior statin exposure, however, a subgroup of patients, especially among Asians, canhaveanti-HMGCRantibodyandmyositisevenwithoutstatinexposure. This indicates a possible a genetic susceptibility to statins. Also, exposure tooystermushroomandredyeastricehavebeenreportedtobeassociated withanti-HMGCRantibodiesinthissubgroupofpatients. Key learning points: Statins can cause muscle related adverse events. 2-11% patients can have mild myalgia and myopathy, however necrotising myopathy is extremely rare (0.1%). Anti-HMCGCR antibodies are associated with statin induced IMNM. IMNM has a protracted course and can continue for years after stopping statins. Long term Immunosuppression is required in IMNM. IVIG is effective in refractory cases. Anti-HMCGCR antibodies can be found in statin naïve patients. Hypothyroidism can potentiate statin induced myopathy. The risk of muscle injury is higher when taking a statin which is extensively metabolised by cytochrome P450 3A4 (CYP3A4) -like simvastatin and atorvastatin, with CYP3A4 inhibitors. Pravastatin, rosuvastatin are preferred in these cases.
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A PARANEOPLASTIC CASE OF DERMATOMYOSITIS
Harold Wilson-Morkeh 1 , and Maresa Carulli 1 1 Rheumatology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom Introduction: Dermatomyositis is a rare idiopathic autoimmune condition predominantly affecting women in their fifth or sixth decades. Both cutaneous manifestations and the symptoms of proximal muscle weakness are well described in the literature, and these can often be found in i2 26 September 2019 ORAL PRESENTATIONS
